Список литературы

Поставить закладку

Менделеева Л.П., Вотякова О.М., Рехтина И.Г. Множественная миелома. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. / ed. Поддубной И.В., Савченко В.Г. Москва, 2018. 213–241 p.
Furukawa Y., Kikuchi J. Molecular pathogenesis of multiple myeloma. // Int. J. Clin. Oncol. 2015. Vol. 20, № 3. P. 413–422.
Lewis E.B. Leukemia, Multiple Myeloma, and Aplastic Anemia in American Radiologists // Science (80-. ). 1963. Vol. 142, № 3598. P. 1492–1494.
Linet M.S., Harlow S.D., McLaughlin J.K. A case-control study of multiple myeloma in whites: chronic antigenic stimulation, occupation, and drug use. // Cancer Res. 1987. Vol. 47, № 11. P. 2978–2981.
Hallek M., Bergsagel P.L., Anderson K.C. Multiple myeloma: increasing evidence for a multistep transformation process. // Blood. 1998. Vol. 91, № 1. P. 3–21.
Kuehl W.M., Bergsagel P.L. Molecular pathogenesis of multiple myeloma and its premalignant precursor. // J. Clin. Invest. 2012. Vol. 122, № 10. P. 3456–3463.
Morgan G.J., Walker B.A., Davies F.E. The genetic architecture of multiple myeloma. // Nat. Rev. Cancer. 2012. Vol. 12, № 5. P. 335–348.
Fonseca R. et al. International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review // Leukemia. Nature Publishing Group, 2009. Vol. 23, № 12. P. 2210–2221.
Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). / ed. Каприна А.Д., Старинского В.В., Петровой Г.В. Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. P. 250.
Бессмельцев С.С. Множественная миелома // Вестник гематологии. 2014. Vol. 10, № 3. P. 6–39.
Durie B.G.M., Salmon S.E. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival // Cancer. 1975. Vol. 36, № 3. P. 842–854.
Greipp P.R. et al. International staging system for multiple myeloma // J. Clin. Oncol. 2005. Vol. 23, № 15. P. 3412–3420.
Palumbo A. et al. Revised international staging system for multiple myeloma: A report from international myeloma working group // J. Clin. Oncol. American Society of Clinical Oncology, 2015. Vol. 33, № 26. P. 2863–2869.
Kyle R.A., Rajkumar S. V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. // Leukemia. 2009. Vol. 23, № 1. P. 3–9.
Moreau P. et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2017. Vol. 28, № suppl_4. P. iv52–iv61.
Rajkumar S.V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma // The Lancet Oncology. Lancet Publishing Group, 2014. Vol. 15, № 12. P. e538–e548.
Coppola A. et al. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. // Semin. Thromb. Hemost. 2011. Vol. 37, № 8. P. 929–945.
Tripathy S. The role of serum protein electrophoresis in the detection of multiple myeloma: An experience of a corporate hospital // J. Clin. Diagnostic Res. 2012. Vol. 6, № 9. P. 1458–1461.
Misra A. et al. Old but Still Relevant: High Resolution Electrophoresis and Immunofixation in Multiple Myeloma // Indian Journal of Hematology and Blood Transfusion. Springer India, 2016. Vol. 32, № 1. P. 10–17.
Любимова Н.В. et al. Свободные легкие цепи иммуноглобулинов в диагностике и прогнозе множественной миеломы. // Альманах клинической медицины. 2017. Vol. 45, № 2. P. 102–108.
Julie D. et al. Comparison of Bone marrow Aspirate and Bone marrow Biopsy in the workup of Patients with Multiple Myeloma // Clin. Lymphoma Myeloma Leuk. Elsevier BV, 2015. Vol. 15. P. e117.
Pianko M.J. et al. Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease // Clinical Cancer Research. American Association for Cancer Research Inc., 2014. Vol. 20, № 23. P. 5888–5897.
Cavo M. et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group // The Lancet Oncology. Lancet Publishing Group, 2017. Vol. 18, № 4. P. e206–e217.
Mateos M.-V., San Miguel J. V. Smoldering multiple myeloma // Hematol. Oncol. 2015. Vol. 33. P. 33–37.
Zou Y. et al. Bortezomib and lenalidomide as front-line therapy for multiple myeloma. // Leuk. Lymphoma. 2014. Vol. 55, № 9. P. 2024–2031.
Mateos M.V. et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial // J. Clin. Oncol. 2010. Vol. 28, № 13. P. 2259–2266.
Bringhen S. et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. // Blood. 2010. Vol. 116, № 23. P. 4745–4753.
Takezako N. et al. The Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients // Blood. 2016. Vol. 128, № 22.
Jagannath S. et al. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. // Br. J. Haematol. 2009. Vol. 146, № 6. P. 619–626.
Weisel K. et al. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. // Leuk. Lymphoma. 2017. Vol. 58, № 1. P. 153–161.
Benboubker L. et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma // N. Engl. J. Med. Massachussetts Medical Society, 2014. Vol. 371, № 10. P. 906–917.
Facon T. et al. Updated Overall Survival (OS) Analysis of the FIRST Study: Lenalidomide Plus Low-Dose Dexamethasone (Rd) Continuous vs Melphalan, Prednisone, and Thalidomide (MPT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) // Clin. Lymphoma Myeloma Leuk. Elsevier BV, 2015. Vol. 15. P. e134.
Palumbo A. et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. // N. Engl. J. Med. 2012. Vol. 366, № 19. P. 1759–1769.
Facon T. et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma // N. Engl. J. Med. Massachusetts Medical Society, 2019. Vol. 380, № 22. P. 2104–2115.
Mateos M. V. et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma // N. Engl. J. Med. Massachussetts Medical Society, 2018. Vol. 378, № 6. P. 518–528.
Durie B.G.M. et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) // Blood Cancer J. Springer Nature, 2020. Vol. 10, № 5.
Durie B.G.M. et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial // Lancet. Lancet Publishing Group, 2017. Vol. 389, № 10068. P. 519–527.
Su B. et al. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents // Leuk. Lymphoma. Taylor and Francis Ltd, 2018.
Dhakal B. et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction a systematic review and meta-analysis // JAMA Oncol. American Medical Association, 2018. Vol. 4, № 3. P. 343–350.
Nooka A.K. et al. Bortezomib-containing induction regimens in transplant-eligible myeloma patients // Cancer. 2013. Vol. 119, № 23. P. 4119–4128.
Leiba M. et al. Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: A meta-analysis // Br. J. Haematol. Blackwell Publishing Ltd, 2014. Vol. 166, № 5. P. 702–710.
Attal M. et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 2017. Vol. 376, № 14. P. 1311–1320.
Rosiñol L. et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma // Blood. American Society of Hematology, 2019. Vol. 134, № 16. P. 1337–1345.
Tuchman S.A., Chao N.J., Gasparetto C.G. Lenalidomide before and after autologous hematopoietic stem cell transplantation in multiple myeloma // Advances in Hematology. 2012. Vol. 2012.
Knop S. et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: A report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom) // Blood. 2009. Vol. 113, № 18. P. 4137–4143.
Reece D.E. et al. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma // Br. J. Haematol. Blackwell Publishing Ltd, 2015. Vol. 168, № 1. P. 46–54.
Fung H.C., Nathan S., Maciejewski J.J. Induction chemotherapy before autologous stem cell transplantation for symptomatic plasma cell myeloma - does it matter? // Clin. Pharmacol. 2010. Vol. 2. P. 71–75.
Tuchman S.A. et al. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma // J. Clin. Apher. Wiley-Liss Inc., 2015. Vol. 30, № 3. P. 176–182.
Hosing C. Hematopoietic stem cell mobilization with G-CSF // Methods Mol. Biol. Humana Press Inc., 2012. Vol. 904. P. 37–47.
Sivaraj D. et al. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma // Bone Marrow Transplant. Nature Publishing Group, 2018. Vol. 53, № 1. P. 34–38.
Oliva S. et al. Minimal residual disease after transplantation or lenalidomidebased consolidation in myeloma patients: A prospective analysis // Oncotarget. Impact Journals LLC, 2017. Vol. 8, № 4. P. 5924–5935.
Sonneveld P. et al. Consolidation followed by maintenance vs. maintenance alone in newly diagnosed, transplant eligible multiple myeloma: a randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM TRIAL) // EHA 23 Proceedings. 2018. P. Abstract S108.
Roussel M. et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: A phase II study by the Intergroupe Francophone du Myélome // J. Clin. Oncol. American Society of Clinical Oncology, 2014. Vol. 32, № 25. P. 2712–2717.
Naumann-Winter F. et al. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. // Cochrane database Syst. Rev. 2012. Vol. 10. P. CD004626.
Nathwani N., Larsen J.T., Kapoor P. Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents // Current Hematologic Malignancy Reports. Current Science Inc., 2016. Vol. 11, № 2. P. 127–136.
Sonneveld P. et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/ GMMG-HD4 trial // J. Clin. Oncol. 2012. Vol. 30, № 24. P. 2946–2955.
McCarthy P.L. et al. Lenalidomide after stem-cell transplantation for multiple myeloma. // N. Engl. J. Med. 2012. Vol. 366, № 19. P. 1770–1781.
Attal M. et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. // N. Engl. J. Med. 2012. Vol. 366, № 19. P. 1782–1791.
Palumbo A. et al. Autologous transplantation and maintenance therapy in multiple myeloma. // N. Engl. J. Med. 2014. Vol. 371, № 10. P. 895–905.
Beurden-Tan C.H.Y.V. et al. Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma // Journal of Clinical Oncology. American Society of Clinical Oncology, 2017. Vol. 35, № 12. P. 1312–1319.
Knopf K.B. et al. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. // Clin. Lymphoma. Myeloma Leuk. 2014. Vol. 14, № 5. P. 380–388.
Scott K. et al. Bortezomib for the treatment of multiple myeloma. // Cochrane database Syst. Rev. 2016. Vol. 4. P. CD010816.
Dimopoulos M.A. et al. A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis // Clin. Lymphoma, Myeloma Leuk. Elsevier Inc., 2018. Vol. 18, № 3. P. 163-173.e6.
Anderson K.C. et al. Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study // J. Clin. Oncol. 2009. Vol. 27, № 15 (Suppl.). P. Abstract 8536.
Shah C. et al. Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: Systematic review and meta-analysis of 14 trials // Oncotarget. Impact Journals LLC, 2018. Vol. 9, № 34. P. 23704–23717.
Moreau P. et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma // N. Engl. J. Med. 2016. Vol. 374, № 17. P. 1621–1634.
Dimopoulos M.A. et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial // Cancer. John Wiley and Sons Inc., 2018. Vol. 124, № 20. P. 4032–4043.
Miguel J.S. et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM- 003): A randomised, open-label, phase 3 trial // Lancet Oncol. 2013. Vol. 14, № 11. P. 1055–1066.
Lokhorst H.M. et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. // N. Engl. J. Med. 2015. Vol. 373, № 13. P. 1207–1219.
Lonial S. et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial // Lancet. Lancet Publishing Group, 2016. Vol. 387, № 10027. P. 1551–1560.
Dimopoulos M.A. et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 2018. Vol. 379, № 19. P. 1811–1822.
Attal M. et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study // Lancet. Lancet Publishing Group, 2019. Vol. 394, № 10214. P. 2096–2107.
Tsang R.W. et al. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. // Int. J. Radiat. Oncol. Biol. Phys. 2018. Vol. 101, № 4. P. 794–808.
Mark D. et al. Local Radiation Therapy for Palliation in Patients With Multiple Myeloma of the Spine. // Front. Oncol. 2019. Vol. 9. P. 601.
Dimopoulos M.A. et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial // Lancet Oncol. Lancet Publishing Group, 2017. Vol. 18, № 10. P. 1327–1337.
Sonneveld P., Broijl A. Treatment of relapsed and refractory multiple myeloma // Haematologica. Ferrata Storti Foundation, 2016. Vol. 101, № 4. P. 396–406.
Dimopoulos M.A. et al. Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group // Journal of Clinical Oncology. American Society of Clinical Oncology , 2010. Vol. 28, № 33. P. 4976–4984.
Снеговой А. В., Абрамов М. Е., Бяхов М. Ю., Владимирова Л. Ю., Возный Э. К., Гладков О. А., Когония Л. М., Кононенко И. Б., Копп М. В., Королева И. А., Ларионова В. Б., Личиницер М. Р., Поддубная И. В. П.В.В. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных. // Практические рекомендации. 2016.
Compagno N. et al. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia // Frontiers in Immunology. Frontiers Media S.A., 2014. Vol. 5, № DEC.
Константинова Т.С., Клясова Г.А., Капланов К.Д. Лечение и профилактика инфекционных осложнений у пациентов с лимфопролиферативными заболеваниями. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. / ed. Поддубная И.В., Савченко В.Г. Москва, 2018. 289–311 p.
Абузарова Г.Р. et al. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России., 2016. 94 p.
Durie B.G.M. et al. International uniform response criteria for multiple myeloma // Leukemia. Nature Publishing Group, 2006. Vol. 20, № 9. P. 1467–1473.
Rajkumar S.V. et al. Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1 // Blood. 2011. Vol. 117, № 18. P. 4691–4695.
Kumar S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma // The Lancet Oncology. Lancet Publishing Group, 2016. Vol. 17, № 8. P. e328–e346.
Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies. // Am. J. Phys. Med. Rehabil. 2011. Vol. 90, № 5 Suppl 1. P. S88-94.
Jones J.R. et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial // Blood Cancer J. 2016. Vol. 6, № 12. P. e506.
Rajkumar S.V. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial // Lancet Oncol. Lancet Publishing Group, 2010. Vol. 11, № 1. P. 29–37.
Punke A.P., Waddell J.A., Solimando D.A. Lenalidomide, bortezomib, and dexamethasone (RVD) regimen for multiple myeloma // Hosp. Pharm. SAGE Publications Ltd, 2017. Vol. 52, № 1. P. 27–32.
Dadacaridou M. et al. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. // J. BUON. Vol. 12, № 1. P. 41–44.
Lakshman A. et al. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma // Am. J. Hematol. 2018. Vol. 93, № 2. P. 179–186.
Krause D.S. et al. CD34: Structure, biology, and clinical utility // Blood. American Society of Hematology, 1996. Vol. 87, № 1. P. 1–13.
Giralt S. et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus guidelines and recommendations // Biology of Blood and Marrow Transplantation. Elsevier, 2014. Vol. 20, № 3. P. 295–308.
Stiff P.J. et al. Transplanted CD34 + Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma // Biol. Blood Marrow Transplant. Biol Blood Marrow Transplant, 2011. Vol. 17, № 8. P. 1146–1153.
Passos-Coelho J.L. et al. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte- macrophage colony-stimulating factor mobilization // J. Clin. Oncol. American Society of Clinical Oncology, 1995. Vol. 13, № 3. P. 705–714.
Hohaus S. et al. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. // Exp. Hematol. 1993. Vol. 21, № 4. P. 508–514.
Покровская О.С., Менделеева Л.П., Гальцева И.В., Варламова Е.Ю., Капланская И.Б., Воробьев И.А., Грецов Е.М., Калинин Н.Н., Варламова С.В., Клясова Г.А., Тихонова Л.Ю. С.В.Г. Мобилизация гемопоэтических клеток крови у больных миеломной болезнью // Проблемы гематологии и переливания. 2003. P. 55–56.
Olivieri A. et al. Proposed definition of “poor mobilizer” in lymphoma and multiple myeloma: An analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo // Bone Marrow Transplant. Bone Marrow Transplant, 2012. Vol. 47, № 3. P. 342–351.
Yang B.B., Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim // Clinical Pharmacokinetics. Clin Pharmacokinet, 2011. Vol. 50, № 5. P. 295–306.
Costa L.J. et al. Pegfilgrastim-versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: Efficacy and cost analysis // Transfusion. Transfusion, 2012. Vol. 52, № 11. P. 2375–2381.
Dale D.C. et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim // Supportive Care in Cancer. Springer Verlag, 2018. Vol. 26, № 1. P. 7–20.
Smith T.J. et al. Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update // J. Clin. Oncol. American Society of Clinical Oncology, 2015. Vol. 33, № 28. P. 3199–3212.
Bilgin Y.M., De Greef G.E. Plerixafor for stem cell mobilization: The current status // Current Opinion in Hematology. Lippincott Williams and Wilkins, 2016. Vol. 23, № 1. P. 67–71.
Бабенецкая Д.В., Моторин Д.В., Петров А.В., Алексеева Ю.А. З.А.Ю. Мобилизация гемопоэтических стволовых клеток препаратами циклофосфамид и цитарабин в сочетании с колониестимулирующим фактором у больных множественной миеломой, кандидатов для проведения трансплантации аутологичных гемопоэтических стволовых клеток // Гематология и трансфузиология. 2017. № 62(4). P. 180-187.
Покровская О.С. Кроветворная ткань и стромальное микроокружение в процессе интенсивной терапии и мобилизации гемопоэтических стволовых клеток у больных множественной миеломой: Автореф. дис.канд.мед.наук. 2011. Vol. 153. 29 p.
Афанасьева О.И., Воинов В.А. Г.Ю.С. Экстракорпоральная гемокоррекция: терминология, языковые соответствия. СПб, 2016. P. 7–15.
Ikeda K. et al. Adverse Events Associated With Infusion of Hematopoietic Stem Cell Products: A Prospective and Multicenter Surveillance Study // Transfusion Medicine Reviews. W.B. Saunders, 2018. Vol. 32, № 3. P. 186–194.
Sutherland D.R. et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry // Journal of Hematotherapy and Stem Cell Research. J Hematother, 1996. Vol. 5, № 3. P. 213–226.
Attal M. et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma // N. Engl. J. Med. 1996. Vol. 335, № 2. P. 91–97.
Fermand J.-P. et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. // J. Clin. Oncol. 2005. Vol. 23, № 36. P. 9227–9233.
Attal M. et al. Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma // N. Engl. J. Med. Massachusetts Medical Society, 2003. Vol. 349, № 26. P. 2495–2502.
Attal M. et al. Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial) // Blood. 2015. Vol. 126, № 23. P. 391–391.
Gay F. et al. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis // Leukemia. 2017. Vol. 31, № 8. P. 1727–1734.
Auner H.W. et al. Infectious complications after autologous hematopoietic stem cell transplantation: Comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma // Ann. Hematol. Ann Hematol, 2002. Vol. 81, № 7. P. 374–377.
Gil L., Styczynski J., Komarnicki M. Infectious complication in 314 patients after high- dose therapy and autologous hematopoietic stem cell transplantation: Risk factors analysis and outcome // Infection. Infection, 2007. Vol. 35, № 6. P. 421–427.
Eleutherakis-Papaiakovou E. et al. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: Results of a single institution, randomized phase 2 trial // Am. J. Hematol. Am J Hematol, 2010. Vol. 85, № 11. P. 863–867.
Neumann S. et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DG // Annals of Hematology. Ann Hematol, 2013. Vol. 92, № 4. P. 433– 442.
Moghnieh R. et al. Bacteraemia post-autologous haematopoietic stem cell transplantation in the absence of antibacterial prophylaxis: a decade’s experience from Lebanon // Infection. Urban und Vogel GmbH, 2018. Vol. 46, № 6.
Клясова Г.А. et al. Эмпирическая антимикробная терапия у больных острыми лейкозами: итоги многоцентрового исследования // Терапевтический архив. 1998. Vol. 70, № 7. P. 15–21.
Lyubimova N. V. et al. Free light chains of immunoglobulins in the diagnosis and prognosis of multiple myeloma // Alm. Clin. Med. Moscow Regional Research and Clinical Institute (MONIKI), 2017. Vol. 45, № 2. P. 102–108.
Bailly C. et al. PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients // Int. J. Mol. Sci. 2017. Vol. 18, № 2. P. 445.
Bartel T.B. et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. // Blood. 2009. Vol. 114, № 10. P. 2068–2076.
Meignan M., Hutchings M., Schwartz L.H. Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose‐Positron Emission Tomography // Oncologist. Wiley, 2015. Vol. 20, № 8. P. 890–895.
Moreau P. et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up // Ann. Oncol. Oxford University Press, 2013. Vol. 24, № SUPPL.6.
Haznedar R. et al. Value of 18 F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma // Eur. J. Nucl. Med. Mol. Imaging. Springer Verlag, 2011. Vol. 38, № 6. P. 1046–1053.
Latifoltojar A. et al. Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response // Br. J. Haematol. Blackwell Publishing Ltd, 2017. Vol. 176, № 2. P. 222–233.
Usmani S.Z. et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3 // Blood. 2013. Vol. 121, № 10. P. 1819–1823.
Stetler-Stevenson M. et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition // Cytom. Part B - Clin. Cytom. 2016.
Goyal S., Singh U.R., Rusia U. Comparative evaluation of bone marrow aspirate with trephine biopsy in hematological disorders and determination of optimum trephine length in lymphoma infiltration // Mediterr. J. Hematol. Infect. Dis. Catholic University in Rome, 2014. Vol. 6, № 1. P. 2014002.
Инструкция по медицинскому применению лекарственного препарата деносумаб (ЛП-000871) - Министерство здравоохранения России, 21 с.
Raje N. et al. Denosumab versus zoledronic acid in bone disease treatment of new ly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study // Lancet Oncol. Lancet Publishing Group, 2018. Vol. 19, № 3. P. 370–381.
Burkiewicz J.S., Scarpace S.L., Bruce S.P. Denosumab in Osteoporosis and Oncology New Drug Developments // Ann. Pharmacother. I. 2009. Vol. 43. P. 1445.
Lacy M.Q. et al. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma // Mayo Clin. Proc. Elsevier Ltd, 2006. Vol. 81, № 8. P. 1047–1053.
Terpos E. et al. The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network // Annals of Oncology. Ann Oncol, 2009. Vol. 20, № 8. P. 1303–1317.
Anderson K. et al. Role of bone-modifying agents in multiple myeloma: American society of clinical oncology clinical practice guideline update // J. Clin. Oncol. American Society of Clinical Oncology, 2018. Vol. 36, № 8. P. 812–818.
Crockett J.C. et al. New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: Focus on the RANK/RANKL axis // Osteoporosis International. Osteoporos Int, 2011. Vol. 22, № 1. P. 1–20.
Mikami S. et al. Invasion and metastasis of renal cell carcinoma // Medical Molecular Morphology. Springer-Verlag Tokyo, 2014. Vol. 47, № 2. P. 63–67.
Terpos E. et al. International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease // J. Clin. Oncol. American Society of Clinical Oncology, 2013. Vol. 31, № 18. P. 2347–2357.
Morgan G.J. et al. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: The Medical Research Council Myeloma IX Trial // Blood. Blood, 2012. Vol. 119, № 23. P. 5374–5383.
Berenson J.R. et al. Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma // N. Engl. J. Med. Massachusetts Medical Society, 1996. Vol. 334, № 8. P. 488–493.
Morgan G.J. et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial // Lancet. Lancet, 2010. Vol. 376, № 9757. P. 1989–1999.
Rosen L.S. et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial // Cancer. Cancer, 2003. Vol. 98, № 8. P. 1735–1744.
Anastasilakis A.D. et al. RANKL inhibition for the management of patients with benign metabolic bone disorders // Expert Opinion on Investigational Drugs. Expert Opin Investig Drugs, 2009. Vol. 18, № 8. P. 1085–1102.
Santini D. et al. Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases // J. Cell. Physiol. J Cell Physiol, 2011. Vol. 226, № 3. P. 780–784.
Casimiro S. et al. RANKL/RANK/MMP-1 Molecular Triad Contributes to the Metastatic Phenotype of Breast and Prostate Cancer Cells In Vitro // PLoS One. PLoS One, 2013. Vol. 8, № 5.
Delmas P.D. Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases // Journal of Clinical Densitometry. J Clin Densitom, 2008. Vol. 11, № 2. P. 325–338.
Sattler A.M. et al. Novel Aspects on RANK Ligand and Osteoprotegerin in Osteoporosis and Vascular Disease // Calcif. Tissue Int. 2004. Vol. 74, № 1. P. 103–106.
Boyce B.F., Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling // Archives of Biochemistry and Biophysics. NIH Public Access, 2008. Vol. 473, № 2. P. 139–146.
Timotheadou E. et al. Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy // Transl. Oncol. Neoplasia Press, Inc., 2017. Vol. 10, № 4. P. 589–598.
Zamagni E. et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation // Blood. Blood, 2011. Vol. 118, № 23. P. 5989–5995.
Hesketh P.J. Chemotherapy-induced nausea and vomiting. // N. Engl. J. Med. N Engl J Med, 2008. Vol. 358, № 23. P. 2482–2494.
DeVita V.T., Chu E. A history of cancer chemotherapy. // Cancer Res. Cancer Res, 2008. Vol. 68, № 21. P. 8643–8653.
Navari R.M., Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 2016. Vol. 374, № 14. P. 1356–1367.
Bountra C. et al. Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. // Oncology. Oncology, 1996. Vol. 53 Suppl 1. P. 102–109.
Mitchelson F. Pharmacological agents affecting emesis. A review (Part I). // Drugs. Drugs, 1992. Vol. 43, № 3. P. 295–315.
Berger M.J. et al. Antiemesis, version 2.2017 featured updates to the NCCN guidelines // JNCCN Journal of the National Comprehensive Cancer Network. Harborside Press, 2017. Vol. 15, № 7. P. 883–893.
Leslie R.A. Neuroactive substances in the dorsal vagal complex of the medulla oblongata: nucleus of the tractus solitarius, area postrema, and dorsal motor nucleus of the vagus. // Neurochem. Int. Neurochem Int, 1985. Vol. 7, № 2. P. 191–211.
Patel P. et al. Aprepitant and fosaprepitant drug interactions: a systematic review. // Br. J. Clin. Pharmacol. Br J Clin Pharmacol, 2017. Vol. 83, № 10. P. 2148–2162.
Roila F. et al. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference // Annals of Oncology. Ann Oncol, 2006. Vol. 17, № 1. P. 20–28.
Basch E. et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update // J. Clin. Oncol. J Clin Oncol, 2011. Vol. 29, № 31. P. 4189–4198.
Hesketh P.J. et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update // Journal of Clinical Oncology. American Society of Clinical Oncology, 2017. Vol. 35, № 28. P. 3240–3261.
Razvi Y. et al. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients // Supportive Care in Cancer. Springer Verlag, 2019. Vol. 27, № 1. P. 87–95.
Burget D.W., Chiverton S.G., Hunt R.H. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression // Gastroenterology. Gastroenterology, 1990. Vol. 99, № 2. P. 345–351.
Ивашкин В.Т. et al. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020. Vol. 30, № 1. P. 49–70.
Scally B. et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials // Lancet Gastroenterol. Hepatol. Elsevier Ltd, 2018. Vol. 3, № 4. P. 231–241.
Hu Z.-H. et al. Efficacy of proton pump inhibitors for patients with duodenal ulcers: A pairwise and network meta-analysis of randomized controlled trials // Saudi J. Gastroenterol. Medknow Publications, 2017. Vol. 23, № 1. P. 11.
Poynard T., Lemaire M., Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer // Eur. J. Gastroenterol. Hepatol. 1995. Vol. 7, № 7. P. 661–665.
Lanas A., Chan F.K.L. Peptic ulcer disease. // Lancet (London, England). Lancet, 2017. Vol. 390, № 10094. P. 613–624.
Conn H.O., Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. // J. Intern. Med. J Intern Med, 1994. Vol. 236, № 6. P. 619–632.
Сытов А.В., Лейдерман И.Н., Ломидзе С.В., Нехаев И.В. Х.А.Ж.. Практические рекомендации по нутритивной поддержке онкологических больных // RUSSCO. 2017. P. 524–532.
Virizuela J.A. et al. Nutritional support and parenteral nutrition in cancer patients: an expert consensus report // Clin. Transl. Oncol. Springer-Verlag Italia s.r.l., 2018. Vol. 20, № 5. P. 619–629.
Бесова Н.С., Борисова Т.Н., Ларионова В.Б., Лейдерман И.Н., Обухова О.А., Попова Т.С., Салтанов А.И., Сельчук В.Ю., Снеговой А.В., Ткачев С.И., Тюляндин С.А. Ш.А.И. Клинические рекомендации по нутритивной поддержке при химиотерапии и/или лучевой терапии. 2014.
Arends J. et al. ESPEN guidelines on nutrition in cancer patients // Clin. Nutr. Churchill Livingstone, 2017. Vol. 36, № 1. P. 11–48.
Camblor-Álvarez M. et al. Soporte nutricional y nutrición parenteral en el paciente oncológico: informe de consenso de un grupo de expertos // Nutr. Hosp. ARAN Ediciones, 2018. Vol. 35, № 1.
Baiu I., Spain D.A. Parenteral Nutrition // JAMA - Journal of the American Medical Association. American Medical Association, 2019. Vol. 321, № 21. P. 2142.
Дементьева И.И., Морозов Ю.А., Чарная М.А. Патология системы гемостаза / ed. Алексина В.А. Москва: ГЭОТАР-МЕД, 2013. 288 p.
Зозуля Н.И. Диагностика и лечение ингибиторной формы гемофилии. Москва, 2010. 260 p.
SPIRIN M., GALSTYAN G., DROKOV M. Central venous access in lymphoma patients (pts) with superior vena cava syndrome (SVCS) // INTENSIVE CARE Med. Exp. 2019. Vol. 7, № Suppl. 3:001341. P. 388–389.
Pluschnig U. et al. Extravasation emergencies: state-of-the-art management and progress in clinical research. // Memo. Springer, 2016. Vol. 9, № 4. P. 226–230.
Zeidler K. et al. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. // Transfusion. 2011. Vol. 51, № 11. P. 2269–2276.
Zerati A.E. et al. Totally implantable venous catheters : history , implantation technique and complications. // J Vasc Bras. 2017. Vol. 16, № 2. P. 128–139.
Gow K.W., Tapper D., Hickman R.O. Between the lines: The 50th anniversary of long- term central venous catheters // Am. J. Surg. Elsevier Ltd, 2017. Vol. 213, № 5. P. 837– 848.
Yeral M. et al. Tunnelled central venous catheter-related problems in the early phase of haematopoietic stem cell transplantation and effects on transplant outcome. // Turkish J. Haematol. Off. J. Turkish Soc. Haematol. Galenos Yayinevi, 2015. Vol. 32, № 1. P. 51– 57.
Maki D.G., Kluger D.M., Crnich C.J. The Risk of Bloodstream Infection in Adults With Different Intravascular Devices: A Systematic Review of 200 Published Prospective Studies // Mayo Clin. Proc. Elsevier, 2006. Vol. 81, № 9. P. 1159–1171.
Hamilton H. Central Venous Catheters / ed. Bodenham A.R. Oxford, UK: Wiley- Blackwell, 2009.
Biffi R. Introduction and Overview of PICC History // Peripherally Inserted Central Venous Catheters. Milano: Springer Milan, 2014. P. 1–6.
Linenberger M.L. Catheter-related thrombosis: risks, diagnosis, and management. // J. Natl. Compr. Canc. Netw. 2006. Vol. 4, № 9. P. 889–901.
Lee A.Y.Y., Kamphuisen P.W. Epidemiology and prevention of catheter-related thrombosis in patients with cancer // J. Thromb. Haemost. 2012. № 10. P. 1491–1499.
Цепенщинков Л.., Лядов В.К. Периферически имплантируемый центральный венозный катетер: обзор литераутры. // Клиническая онкогематология. 2014. Vol. 7, № 2. P. 220–228.
Linder L.E. et al. Material thrombogenicity in central venous catheterization: a comparison between soft, antebrachial catheters of silicone elastomer and polyurethane. // JPEN. J. Parenter. Enteral Nutr. 1984. Vol. 8, № 4. P. 399–406.
Watters V.A., Grant J.P. Use of Electrocardiogram to Position Right Atrial Catheters During Surgery // Ann. Surg. Vol. 225, № 2. P. 165–171.
Taal M.W., Chesterton L.J., McIntyre C.W. Venography at insertion of tunnelled internal jugular vein dialysis catheters reveals significant occult stenosis // Nephrol. Dial. Transplant. Oxford University Press, 2004. Vol. 19, № 6. P. 1542–1545.
Lobato E.B. et al. Cross-sectional area of the right and left internal jugular veins. // J. Cardiothorac. Vasc. Anesth. 1999. Vol. 13, № 2. P. 136–138.
Червонцева А.М. Повреждение сосудистого эндотелия в процессе лечения острых миелоидных лейкозов. 2008.
Багирова Н.С. Инфекции, связанные с внутрисосудистыми устройствами: терминология, диагностика, профилактика и терапия // Злокачественные опухоли. 2014. № 3. P. 164–171.
Bannon M.P., Heller S.F., Rivera M. Anatomic considerations for central venous cannulation. // Risk Manag. Healthc. Policy. Dove Press, 2011. Vol. 4. P. 27–39.
Milling T.J. et al. Randomized, controlled clinical trial of point-of-care limited ultrasonography assistance of central venous cannulation: The Third Sonography Outcomes Assessment Program (SOAP-3) Trial* // Crit. Care Med. 2005. Vol. 33, № 8. P. 1764–1769.
Tordoir J. et al. EBPG on Vascular Access // Nephrol. Dial. Transplant. Oxford University Press, 2007. Vol. 22, № Supplement 2. P. ii88–ii117.
Roca-Tey R. Permanent Arteriovenous Fistula or Catheter Dialysis for Heart Failure Patients // J. Vasc. Access. SAGE PublicationsSage UK: London, England, 2016. Vol. 17, № 1_suppl. P. 23–29.
Aksoy S. et al. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: A systematic review and meta-analysis // Leuk. Lymphoma. Leuk Lymphoma, 2009. Vol. 50, № 3. P. 357–365.
Hua Q., Zhu Y., Liu H. Severe and fatal adverse events risk associated with rituximab addition to b-cell non-hodgkin’s lymphoma (B-NHL) chemotherapy: A meta-analysis // J. Chemother. 2015.
Ren Y.R. et al. Rituximab treatment strategy for patients with diffuse large B‑cell lymphoma after first‑line therapy: A systematic review and meta‑analysis // Chin. Med. J. (Engl). Chinese Medical Association, 2015. Vol. 128, № 3. P. 378–383.
Hoering A. et al. End points and statistical considerations in immuno-oncology trials: Impact on multiple myeloma // Future Oncology. Future Medicine Ltd., 2017. Vol. 13, № 13. P. 1181–1193.
Hirayama F. Current understanding of allergic transfusion reactions: Incidence, pathogenesis, laboratory tests, prevention and treatment // British Journal of Haematology. Br J Haematol, 2013. Vol. 160, № 4. P. 434–444.
Lonial S. et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma // J. Clin. Oncol. 2012. Vol. 30, № 16. P. 1953–1959.
Dimopoulos M.A. et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 2016. Vol. 375, № 14. P. 1319–1331.
Boyle E.M. et al. Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial // Br. J. Haematol. Blackwell Publishing Ltd, 2019. Vol. 187, № 3. P. 319–327.
Baldo B.A., Baldo B.A. Monoclonal Antibodies Approved for Cancer Therapy // Safety of Biologics Therapy. Springer International Publishing, 2016. P. 57–140.
Van De Donk N.W.C.J. et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma // Blood. American Society of Hematology, 2016. Vol. 127, № 6. P. 681–695.
Tinegate H. et al. Guideline on the investigation and management of acute transfusion reactions Prepared by the BCSH Blood Transfusion Task Force // Br. J. Haematol. Br J Haematol, 2012. Vol. 159, № 2. P. 143–153.
Taniwaki M. et al. Elotuzumab for the treatment of relapsed or refractory multiple myeloma, with special reference to its modes of action and SLAMF7 signaling // Mediterranean Journal of Hematology and Infectious Diseases. Universita Cattolica del Sacro Cuore, 2018. Vol. 10, № 1. P. 2018014.
Gentili S., Lonial S. Relapsed and Refractory Multiple Myeloma: New Therapeutic Strategies // Hematology/Oncology Clinics of North America. W.B. Saunders, 2014. Vol. 28, № 5. P. 861–890.
Sato K., Kohgo Y. Infusion reactions // Gan To Kagaku Ryoho. Clin J Oncol Nurs, 2008. Vol. 35, № 10. P. 1671–1674.
Annibali O. et al. Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature // Critical Reviews in Oncology/Hematology. Elsevier Ireland Ltd, 2018. Vol. 124. P. 41–50.
Sanfilippo K.M. et al. Incidence of venous thromboembolism in patients with non- Hodgkin lymphoma // Thromb. Res. Elsevier Ltd, 2016. Vol. 143. P. 86–90.
De Stefano V. et al. Haemostatic alterations induced by treatment with asparaginases and clinical consequences // Thrombosis and Haemostasis. Schattauer GmbH, 2015. Vol. 113, № 2. P. 247–261.
Воробьев А.И. et al. Острая массивная кровопотеря. Москва: ГЭОТАР-МЕД, 2001. 200 p.
Weitz I.C. et al. Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation // Thromb. Haemost. 2002. Vol. 88, № 2. P. 213–220.
Falanga A., Marchetti M., Russo L. Venous thromboembolism in the hematologic malignancies // Current Opinion in Oncology. Curr Opin Oncol, 2012. Vol. 24, № 6. P. 702–710.
Talamo G.P. et al. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism // Blood Coagul. Fibrinolysis. 2009. Vol. 20, № 5. P. 337–339.
Kristinsson S.Y. Thrombosis in multiple myeloma. // Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. Hematology Am Soc Hematol Educ Program, 2010. Vol. 2010. P. 437–444.
Lekovic D., Miljic P., Mihaljevic B. Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma // Thromb. Res. 2010. Vol. 126, № 6. P. 477–480.
Zangari M. et al. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: Review of data from phase 3 trials and studies of novel combination regimens // Clin. Lymphoma, Myeloma Leuk. Elsevier Inc., 2011. Vol. 11, № 2. P. 228–236.
Ranta S. et al. Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia // Blood Coagul. Fibrinolysis. Blood Coagul Fibrinolysis, 2013. Vol. 24, № 7. P. 749–756.
Rozen L. et al. Different profile of thrombin generation in children with acute lymphoblastic leukaemia treated with native or pegylated asparaginase: A cohort study // Pediatr. Blood Cancer. John Wiley and Sons Inc., 2017. Vol. 64, № 2. P. 294–301.
Lauw M.N. et al. Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation // Thromb. Haemost. Thromb Haemost, 2013. Vol. 109, № 4. P. 633–642.
Caruso V. et al. Thrombotic complications in childhood acute lymphoblastic leukemia: A meta-analysis of 17 prospective studies comprising 1752 pediatric patients // Blood. American Society of Hematology, 2006. Vol. 108, № 7. P. 2216–2222.
Mizrahi T. et al. ABO Group as a Thrombotic Risk Factor in Children With Acute Lymphoblastic Leukemia // J. Pediatr. Hematol. Oncol. Lippincott Williams and Wilkins, 2015. Vol. 37, № 5. P. e328–e332.
Merlen C. et al. L-Asparaginase lowers plasma antithrombin and mannan-binding-lectin levels: Impact on thrombotic and infectious events in children with acute lymphoblastic leukemia // Pediatr. Blood Cancer. John Wiley and Sons Inc., 2015. Vol. 62, № 8. P. 1381–1387.
Akselrod B.A. et al. Clinical guidelines for red blood cell transfusion // Gematologiya i Transfusiologiya. Izdatel’stvo Meditsina, 2018. Vol. 63, № 4. P. 372–435.
Kelsey P. et al. Guidelines for the use of platelet transfusions // Br. J. Haematol. 2003. Vol. 122, № 1. P. 10–23.
Баркаган З.С. Геморрагические заболевания и синдромы. Москва: Медицина, 1988. 528 p.
Estcourt L. et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation // Cochrane Database Syst. Rev. Wiley, 2012. № 5.
Stanworth S.J. et al. Platelet transfusion prophylaxis for patients with haematological malignancies: where to now? // Br. J. Haematol. John Wiley & Sons, Ltd, 2005. Vol. 131, № 5. P. 588–595.
Stanworth S.J. et al. A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 2013. Vol. 368, № 19. P. 1771–1780.
Kaufman R.M. et al. Platelet transfusion: A clinical practice guideline from the AABB // Annals of Internal Medicine. American College of Physicians, 2015. Vol. 162, № 3. P. 205–213.
Об утверждении правил клинического использования донорской крови и (или) ее компонентов: Приказ Министерства здравоохранения РФ от 02.04.2013 N 183н // Российская газета - Федеральный выпуск № 190(6166).
Савченко В.Г., Михайлова К.Е.А. Алгоритмы диагностики и протоколы лечения заболеваний системы крови.
Tinmouth A.T., Freedman J. Prophylactic platelet transfusions: Which dose is the best dose? A review of the literature // Transfus. Med. Rev. W.B. Saunders, 2003. Vol. 17, № 3. P. 181–193.
Chen C.-Y. et al. Clinical and Microbiological Characteristics of Perianal Infections in Adult Patients with Acute Leukemia // PLoS One / ed. Heimesaat M.M. Public Library of Science, 2013. Vol. 8, № 4. P. e60624.
Vogel J.D. et al. Clinical Practice Guideline for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula // Diseases of the Colon and Rectum. Lippincott Williams and Wilkins, 2016. Vol. 59, № 12. P. 1117–1133.
Morcos B. et al. Contemporary management of perianal conditions in febrile neutropenic patients // Eur. J. Surg. Oncol. Eur J Surg Oncol, 2013. Vol. 39, № 4. P. 404–407.
Debast S.B. et al. European society of clinical microbiology and infectious diseases: Update of the treatment guidance document for Clostridium difficile infection // Clin. Microbiol. Infect. Blackwell Publishing Ltd, 2014. Vol. 20, № S2. P. 1–26.
Jones E.M., MacGowan A.P. Antimicrobial chemotherapy of human infection due to Listeria monocytogenes // European Journal of Clinical Microbiology & Infectious Diseases. Springer-Verlag, 1995. Vol. 14, № 3. P. 165–175.
Rodríguez-Baño J. et al. Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish society of infectious diseases and clinical microbiology // Enferm. Infecc. Microbiol. Clin. Elsevier Doyma, 2015. Vol. 33, № 5. P. 337.e1-337.e21.
Plumb A.A. et al. Perianal Sepsis in Hematologic Malignancy: MR Imaging Appearances and Distinction from Cryptoglandular Infection in Immunocompetent Patients // Radiology. Radiological Society of North America Inc., 2015. Vol. 276, № 1. P. 147–155.
Ashkar C. et al. Perianal sepsis in neutropaenic patients with haematological malignancies: the role of magnetic resonance imaging and surgery // ANZ J. Surg. Blackwell Publishing, 2020. Vol. 90, № 9. P. 1642–1646.
Solmaz S. et al. Anorectal complications during neutropenic period in patients with hematologic diseases // Mediterr. J. Hematol. Infect. Dis. Universita Cattolica del Sacro Cuore, 2016. Vol. 8, № 1.
Shtyrkova S. V. et al. PERIANAL INFECTIOUS COMPLICATIONS IN PATIENTS WITH GRANULOCYTOPENIA AND HAEMATOLOGICAL MALIGNANCIES // Koloproktologia. Russian Association of Coloproctology, 2020. Vol. 19, № 4. P. 10–31.
Grewal H. et al. Anorectal disease in neutropenic leukemic patients - Operative vs. nonoperative management // Dis. Colon Rectum. Springer-Verlag, 1994. Vol. 37, № 11. P. 1095–1099.
Maertens J. et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: Summary of the ECIL 32009 update // Bone Marrow Transplant. Nature Publishing Group, 2011. Vol. 46, № 5. P. 709–718.
Клясова Г.А. Инфекции при гемобластозах и депрессиях кроветворения: клиника, диагностика и лечение. 2009.
Okhmat V.A. et al. Infections on different chemotherapy cycles in adult patients with acute lymphoblastic leukemia treated with ALL-2009 protocol // Oncogematologiya. ABV-Press Publishing House, 2017. Vol. 12, № 3. P. 31–40.
Averbuch D. et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: Summary of the 2011 4th European Conference on Infections in Leukemia // Haematologica. Ferrata Storti Foundation, 2013. Vol. 98, № 12. P. 1826–1835.
Chang H. et al. Clinical Features and Recurrence Pattern of Perianal Abscess in Patients with Acute Myeloid Leukemia // Acta Haematol. S. Karger AG, 2017. Vol. 138, № 1. P. 10–13.
Савченко В.Г. и др. Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Москва: Практика, 2018. 1008 p.
Maertens J. et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients // Journal of Antimicrobial Chemotherapy. Oxford University Press, 2016. Vol. 71, № 9. P. 1–8.
Young P. et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: The SPLIT randomized clinical trial // JAMA -J. Am. Med. Assoc. American Medical Association, 2015. Vol. 314, № 16. P. 1701–1710.
Bagirova N.S. INFECTIONS ASSOCIATED WITH INTRAVASCULAR DEVICES: TERMINOLOGY, DIAGNOSIS, PREVENTION AND THERAPY // Malig. tumours. Fond Oncoprogress, 2015. Vol. 0, № 3. P. 164.
Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group // Am. J. Clin. Oncol. 1982. Vol. 5, № 6. P. 649–655.